Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations

Abstract Among tyrosine kinase inhibitors, quinazoline-based compounds represent a large and well-known group of multi-target agents. Our previous studies have shown interesting kinases inhibition activity for a series of 4-aminostyrylquinazolines based on the CP-31398 scaffold. Here, we synthesised a new series of styrylquinazolines with a thioaryl moiety in the C4 position and evaluated in detail their biological activity. Our results showed high inhibition potential against non-receptor tyrosine kinases for several compounds. Molecular docking studies showed differential binding to the DFG conformational states of ABL kinase for two derivatives. The compounds showed sub-micromolar activity against leukaemia. Finally, in-depth cellular studies revealed the full landscape of the mechanism of action of the most active compounds. We conclude that S4-substituted styrylquinazolines can be considered as a promising scaffold for the development of multi-kinase inhibitors targeting a desired binding mode to kinases as effective anticancer drugs.

[1]  G. Kramer-Marek,et al.  Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations , 2022, OncoTargets and therapy.

[2]  G. Brumatti,et al.  BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia , 2022, Pharmaceutics.

[3]  S. Grzesiek,et al.  Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket , 2022, Magnetic resonance.

[4]  A. A. Abdelhamid,et al.  Design and synthesis of new triarylimidazole derivatives as dual inhibitors of BRAFV600E/p38α with potential antiproliferative activity , 2021, Journal of Molecular Structure.

[5]  M. Soellner,et al.  Synergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase. , 2021, Angewandte Chemie.

[6]  R. Musioł,et al.  Novel Benzenesulfonate Scaffolds with a High Anticancer Activity and G2/M Cell Cycle Arrest , 2021, Cancers.

[7]  N. Watanabe,et al.  Paradoxical activation of c-Src as a drug-resistant mechanism. , 2021, Cell reports.

[8]  Z. Ryoo,et al.  Imatinib and GNF-5 Exhibit an Inhibitory Effect on Growth of Hepatocellar Carcinoma Cells by Downregulating S-phase Kinase-associated Protein 2 , 2020, Journal of cancer prevention.

[9]  C. Kalodimos,et al.  Conformational states dynamically populated by a kinase determine its function , 2020, Science.

[10]  R. Musioł,et al.  The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors , 2020, Cancers.

[11]  J. Cayuela,et al.  Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. , 2019, Cancer cell.

[12]  J. Polanski,et al.  Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety. , 2019, European journal of medicinal chemistry.

[13]  R. Musioł,et al.  The synthesis and anticancer activity of 2-styrylquinoline derivatives. A p53 independent mechanism of action. , 2019, European journal of medicinal chemistry.

[14]  Sonya M. Hanson,et al.  What Makes a Kinase Promiscuous for Inhibitors? , 2019, Cell chemical biology.

[15]  R. Musioł,et al.  The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series. , 2019, European journal of medicinal chemistry.

[16]  F. Lombardo,et al.  Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. , 2018, Journal of medicinal chemistry.

[17]  J. Polanski,et al.  Iron Chelators and Exogenic Photosensitizers. Synergy through Oxidative Stress Gene Expression , 2017, Journal of Cancer.

[18]  A. Morotti,et al.  The p53 orbit in chronic myeloid leukemia: time to move to patient care , 2016 .

[19]  M. McCarthy,et al.  Oxidation increases the strength of the methionine-aromatic interaction , 2015, Nature chemical biology.

[20]  V. Kryštof,et al.  Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action , 2015, PloS one.

[21]  Roland L. Dunbrack,et al.  Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors , 2014, Journal of medicinal chemistry.

[22]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[23]  S. Ikawa,et al.  c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage. , 2014, Cellular Signalling.

[24]  D. Fabbro,et al.  Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate. , 2014, Methods in enzymology.

[25]  Lukasz Skóra,et al.  NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors , 2013, Proceedings of the National Academy of Sciences.

[26]  P. Evans,et al.  Halonium ion triggered rearrangement of unsaturated benzo-annulated bi- and tricyclic sulfonamides. , 2013, The Journal of organic chemistry.

[27]  D. Gibbons,et al.  Through the open door: Preferential binding of dasatinib to the active form of BCR‐ABL unveiled by in silico experiments , 2013, Molecular oncology.

[28]  M. Gerdes,et al.  A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis , 2013, Genes, chromosomes & cancer.

[29]  John R Engen,et al.  Structure and Dynamic Regulation of Abl Kinases* , 2013, The Journal of Biological Chemistry.

[30]  O. Ottmann,et al.  Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I , 2012, BMC Cancer.

[31]  V. Baichwal,et al.  Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor. , 2012, Journal of medicinal chemistry.

[32]  D. Tang,et al.  Abl regulates smooth muscle cell proliferation by modulating actin dynamics and ERK1/2 activation. , 2012, American journal of physiology. Cell physiology.

[33]  M. Rosner,et al.  An integrated view of cyclin E function and regulation , 2012, Cell cycle.

[34]  A. Furlan,et al.  Abl interconnects oncogenic Met and p53 core pathways in cancer cells , 2011, Cell Death and Differentiation.

[35]  D. Cross,et al.  Inhibitors of the Tyrosine Kinase EphB4. Part 3. Identification of Non-benzodioxole-Based Kinase Inhibitors. , 2011 .

[36]  J. Colicelli,et al.  ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity , 2010, Science Signaling.

[37]  Wolfgang Jahnke,et al.  Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. , 2010, Biochimica et biophysica acta.

[38]  K. Akamanchi,et al.  A Simple, Fast and Chemoselective Method for the Preparation of Arylthiols. , 2010 .

[39]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[40]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[41]  K. Akamanchi,et al.  A Simple, Fast and ChemoselectiveMethod for the Preparation of Arylthiols , 2009 .

[42]  J. Polanski,et al.  Investigating Biological Activity Spectrum for Novel Styrylquinazoline Analogues , 2009, Molecules.

[43]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[44]  T. Smithgall,et al.  Abl N-terminal cap stabilization of SH3 domain dynamics. , 2008, Biochemistry.

[45]  Jon Read,et al.  Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. , 2008, Bioorganic & medicinal chemistry letters.

[46]  A. Boureux,et al.  The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells , 2007, Oncogene.

[47]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[48]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[49]  M. Izquierdo,et al.  Cyclin E1 knockdown induces apoptosis in cancer cells , 2006, Neurological research.

[50]  S. Lowe,et al.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Harald Schwalbe,et al.  NMR characterization of kinase p38 dynamics in free and ligand-bound forms. , 2006, Angewandte Chemie.

[52]  M. Mauro.  Defining and managing imatinib resistance. , 2006, Hematology. American Society of Hematology. Education Program.

[53]  D. Fabbro,et al.  The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. , 2005, Structure.

[54]  Y. Matsuo,et al.  The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. , 2005, Blood.

[55]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[56]  Jessica S Tashker,et al.  Bcr-Abl-Mediated Protection from Apoptosis Downstream of Mitochondrial Cytochrome c Release , 2004, Molecular and Cellular Biology.

[57]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[58]  S. Mazumder,et al.  A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. , 2004, Current cancer drug targets.

[59]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[60]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[61]  G. Superti-Furga,et al.  A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.

[62]  T. Skorski,et al.  BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability , 2002, Oncogene.

[63]  R. Fishel,et al.  Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis , 2002, Molecular and Cellular Biology.

[64]  C. Sawyers,et al.  c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Wick,et al.  Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation. , 1999, Biochemistry.

[66]  E. Buchdunger,et al.  Bcr‐Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors , 1998, British journal of haematology.

[67]  J. Wang,et al.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins , 1993, Molecular and cellular biology.